| AKT inhibition in solid tumors with AKT1 mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251, 2017 | 284 | 2017 |
| Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ... Nature medicine 25 (5), 738-743, 2019 | 237 | 2019 |
| AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity JHL Fok, A Ramos-Montoya, M Vazquez-Chantada, PWG Wijnhoven, ... Nature communications 10 (1), 5065, 2019 | 231 | 2019 |
| Biomarkers of apoptosis TH Ward, J Cummings, E Dean, A Greystoke, JM Hou, A Backen, ... British journal of cancer 99 (6), 841-846, 2008 | 157 | 2008 |
| Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ... The lancet oncology 20 (3), 383-393, 2019 | 155 | 2019 |
| Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells RL Lloyd, PWG Wijnhoven, A Ramos-Montoya, Z Wilson, G Illuzzi, ... Oncogene 39 (25), 4869-4883, 2020 | 140 | 2020 |
| Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours E Dean, MR Middleton, T Pwint, H Swaisland, J Carmichael, ... British journal of cancer 106 (3), 468-474, 2012 | 136 | 2012 |
| First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors G Falchook, J Infante, HT Arkenau, MR Patel, E Dean, E Borazanci, ... EClinicalMedicine 34, 2021 | 131 | 2021 |
| First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ... Clinical cancer research 21 (15), 3412-3419, 2015 | 127 | 2015 |
| A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors JC Soria, HK Gan, SP Blagden, R Plummer, HT Arkenau, M Ranson, ... Annals of Oncology 27 (12), 2268-2274, 2016 | 120 | 2016 |
| An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib J Mateo, V Moreno, A Gupta, SB Kaye, E Dean, MR Middleton, ... Targeted oncology 11, 401-415, 2016 | 116 | 2016 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 115 | 2018 |
| Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer E Dean, D Jodrell, K Connolly, S Danson, J Jolivet, J Durkin, S Morris, ... Journal of clinical oncology 27 (10), 1660-1666, 2009 | 113 | 2009 |
| IAPs as a target for anticancer therapy S Danson, E Dean, C Dive, M Ranson Current Cancer Drug Targets 7 (8), 785-794, 2007 | 93 | 2007 |
| Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers J Cortes, K Tamura, DJ DeAngelo, J De Bono, D Lorente, M Minden, ... British journal of cancer 118 (11), 1425-1433, 2018 | 90 | 2018 |
| Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine±cisplatin in patients with advanced solid tumours MR Middleton, E Dean, TRJ Evans, GI Shapiro, J Pollard, BS Hendriks, ... British journal of cancer 125 (4), 510-519, 2021 | 74 | 2021 |
| Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic EJ Dean, M Ranson, F Blackhall, SV Holt, C Dive Cancer treatment reviews 33 (2), 203-212, 2007 | 72 | 2007 |
| Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. F Andre, M Ranson, E Dean, A Varga, R Van der Noll, PK Stockman, ... Cancer research 73 (8_Supplement), LB-145-LB-145, 2013 | 71 | 2013 |
| Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy R Kim, M Kwon, M An, ST Kim, SA Smith, AB Loembé, PGS Mortimer, ... Annals of Oncology 33 (2), 193-203, 2022 | 69 | 2022 |
| X-linked inhibitor of apoptosis protein as a therapeutic target EJ Dean, M Ranson, F Blackhall, C Dive Expert opinion on therapeutic targets 11 (11), 1459-1471, 2007 | 64 | 2007 |
